Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

Last Close
Jan 08  •  04:00PM ET
37.77
Dollar change
-2.23
Percentage change
-5.57
%
IndexRUT P/E- EPS (ttm)-1.03 Insider Own15.40% Shs Outstand106.33M Perf Week-6.51%
Market Cap4.02B Forward P/E- EPS next Y-1.19 Insider Trans-0.59% Shs Float89.96M Perf Month-6.11%
Enterprise Value3.72B PEG- EPS next Q-0.30 Inst Own69.20% Short Float14.19% Perf Quarter357.26%
Income-94.44M P/S- EPS this Y3.13% Inst Trans-3.24% Short Ratio3.22 Perf Half Y675.56%
Sales0.00M P/B11.64 EPS next Y-9.90% ROA-27.78% Short Interest12.77M Perf YTD-6.51%
Book/sh3.25 P/C13.58 EPS next 5Y-6.83% ROE-29.12% 52W High48.26 -21.74% Perf Year561.47%
Cash/sh2.78 P/FCF- EPS past 3/5Y17.43% 16.38% ROIC-33.18% 52W Low1.87 1925.20% Perf 3Y330.18%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility7.30% 6.19% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM12.45% Oper. Margin- ATR (14)2.46 Perf 10Y-
Dividend Ex-Date- Quick Ratio19.52 Sales Y/Y TTM- Profit Margin- RSI (14)51.75 Recom1.09
Dividend Gr. 3/5Y- - Current Ratio19.52 EPS Q/Q4.75% SMA20-8.91% Beta-0.28 Target Price50.50
Payout- Debt/Eq0.00 Sales Q/Q- SMA5024.33% Rel Volume0.69 Prev Close40.00
Employees59 LT Debt/Eq0.00 EarningsNov 10 AMC SMA200229.60% Avg Volume3.96M Price37.77
IPOFeb 05, 2021 Option/ShortYes / Yes EPS/Sales Surpr.8.26% - Trades Volume2,740,165 Change-5.57%
Date Action Analyst Rating Change Price Target Change
Nov-04-25Upgrade H.C. Wainwright Neutral → Buy $20
Nov-03-25Upgrade William Blair Mkt Perform → Outperform
Oct-15-25Initiated Truist Buy $20
Sep-17-25Initiated Barclays Overweight $15
Sep-04-25Resumed H.C. Wainwright Neutral
Feb-28-25Initiated William Blair Mkt Perform
Oct-31-24Initiated Oppenheimer Outperform $82
Jun-22-23Initiated Mizuho Buy $16
Jun-07-23Initiated Jefferies Buy $18
May-31-23Initiated ROTH MKM Buy $23
Jan-07-26 04:05PM
Jan-02-26 04:05PM
Dec-19-25 03:14PM
Dec-15-25 06:47PM
Dec-14-25 02:40PM
04:05PM Loading…
Dec-11-25 04:05PM
Dec-09-25 11:30PM
03:31PM
02:23PM
06:12AM
Dec-08-25 02:45PM
Dec-04-25 07:57AM
Nov-23-25 07:02AM
Nov-18-25 12:43AM
Nov-17-25 12:15PM
04:05PM Loading…
Nov-14-25 04:05PM
Nov-10-25 04:05PM
Nov-04-25 04:05PM
Nov-03-25 09:05AM
Oct-24-25 04:58AM
Oct-21-25 04:05PM
Oct-02-25 04:05PM
Sep-21-25 10:45AM
Aug-21-25 04:05PM
Aug-07-25 09:55AM
Aug-05-25 04:05PM
Aug-04-25 04:05PM
Jun-23-25 04:07PM
May-29-25 04:05PM
May-14-25 09:30AM
07:54AM Loading…
May-09-25 07:54AM
May-08-25 04:05PM
May-02-25 04:05PM
Apr-30-25 04:05PM
Apr-26-25 08:50AM
Apr-07-25 09:35AM
Apr-03-25 09:35AM
Apr-02-25 04:05PM
Mar-26-25 12:00PM
Mar-20-25 04:05PM
Mar-09-25 10:03AM
Feb-26-25 04:05PM
Feb-25-25 08:05AM
03:00AM
Feb-24-25 04:05PM
Feb-20-25 04:05PM
Feb-05-25 04:05PM
Feb-03-25 04:05PM
Jan-08-25 04:05PM
Jan-02-25 04:05PM
Dec-16-24 01:10PM
Dec-03-24 07:00AM
Dec-02-24 04:05PM
Nov-18-24 04:05PM
Nov-12-24 04:05PM
Nov-06-24 04:05PM
Oct-07-24 04:05PM
Sep-24-24 03:22AM
Sep-18-24 10:07AM
Sep-17-24 01:30AM
Sep-15-24 07:21AM
06:09AM
Sep-14-24 10:12AM
Sep-12-24 07:00PM
Sep-10-24 10:50PM
04:52AM
Sep-09-24 04:01PM
09:58AM
09:24AM
08:06AM
07:05AM
Aug-28-24 09:55AM
Aug-05-24 09:56PM
04:05PM
Aug-02-24 01:54PM
Aug-01-24 04:05PM
Jul-29-24 04:05PM
Jul-26-24 06:40PM
Jul-20-24 09:30AM
Jun-21-24 06:30PM
Jun-19-24 01:27PM
Jun-04-24 09:55AM
Jun-03-24 04:10PM
May-30-24 08:05AM
May-17-24 04:05PM
May-13-24 01:53PM
09:32AM
08:05AM
May-08-24 04:05PM
May-07-24 04:05PM
May-03-24 04:05PM
Apr-29-24 04:05PM
Apr-10-24 04:05PM
Mar-14-24 04:05PM
Mar-11-24 04:05PM
Mar-07-24 04:05PM
Feb-27-24 04:05PM
Feb-07-24 04:05PM
08:05AM
Feb-02-24 04:05PM
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Burroughs Amy L.Chief Executive OfficerJan 02 '26Option Exercise4.6421,55199,99760,315Jan 06 08:26 PM
Burroughs Amy L.Chief Executive OfficerJan 05 '26Sale38.1071,3392,718,230138,976Jan 06 08:26 PM
Kuriakose EmilChief Medical OfficerJan 02 '26Sale38.571,15544,55250,365Jan 06 08:25 PM
Quigley Jill M.DirectorNov 04 '25Option Exercise9.2424,520226,56524,520Nov 05 06:17 PM
Quigley Jill M.DirectorNov 04 '25Sale18.0024,520441,3600Nov 05 06:17 PM
JILL QUIGLEYDirectorNov 04 '25Proposed Sale14.0324,520344,016Nov 04 04:32 PM
Kuriakose EmilChief Medical OfficerOct 01 '25Sale7.859447,40751,520Oct 02 07:24 PM
Kuriakose EmilChief Medical OfficerJul 01 '25Sale4.278533,64052,464Jul 03 02:55 PM
Gengos AndrewChief Financial OfficerJun 27 '25Buy3.9310,00039,28325,000Jun 30 05:38 PM
Burroughs Amy L.Chief Executive OfficerJun 25 '25Buy3.8723,31490,23047,083Jun 25 06:08 PM
Gengos AndrewChief Financial OfficerJun 13 '25Buy3.7310,00037,35010,000Jun 16 06:05 PM
Gengos AndrewChief Financial OfficerJun 16 '25Buy3.955,00019,73215,000Jun 16 06:05 PM
Kuriakose EmilChief Medical OfficerApr 01 '25Sale2.499522,36653,317Apr 02 06:48 PM